Actively Recruiting
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
Led by Sun Yat-sen University · Updated on 2019-10-23
346
Participants Needed
1
Research Sites
413 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
J
JiangXi Province Tumor Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with IMRT alone.
CONDITIONS
Official Title
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
1.Pathologically or clinically confirmed rT3/T4 locally recurrent nasopharyngeal carcinoma;
2.No evidence of distant metastasis
3.More than 1 year from the end of the first course of radiotherapy
4.Male, or female not in the phase of lactating or pregnancy
5.ECOG 0-2
6.Aged 18-70 years old
7.WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L, Hb ≥9g/L
8.Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of upper normal limits
9.Written informed consort signed
You will not qualify if you...
- Only regionally recurrence
- Evidence of distant metastasis
- Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the bladder, oral cavity, or cervix are all permissible) are permitted
- Severe, active co-morbidity
- Prior anti-tumor treatment after diagnosis of local recurrence
- MRI was not performed 3 months after the first course of radiotherapy
- Abnormal function of heart, brain and lungs, etc
- Lactation or pregnancy
- Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
WangHanYu
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
F
Fei Han, doctor
CONTACT
H
hanyu wang, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here